Treatment of Cartilage Lesions with Regentis GelrinC®

If you suffer from knee pain due to a cartilage injury, you may be eligible for a study on new treatments.

Principle Investigators:
Brian J. Cole, M.D., M.B.A.
Adam B. Yanke, M.D.
Brian Forsythe, M.D.

CLINICAL TRIAL PROTOCOL DESCRIPTION

This is a clinical investigation of the efficacy of GelrinC® (Regentis, Or-Akiva, Israel) augmented microfracture for the treatment of isolated cartilage lesions. The full terms of the investigation are detailed and disclosed in the patient consent form and will be described to patients by the physician or research coordinator upon inquiry. Eligible patients may be contact by either the physician or research coordinator prior to their scheduled surgery.

CLINICAL TRIAL ELIGIBILITY CRITERIA

This clinical trial is a new approach to treatment of cartilage lesions with microfracture. To be eligible for this study, you must:

- Be between the ages of 18 and 50 years old
- Be willing to undergo initial evaluation, imaging and post-operative requirements
- Have a cartilage lesion indicated for treatment with GelrinC® augmented microfracture (determined by physician and trial coordinators)

If you are interested in this trial, contact biologicstudies@rushortho.com or call 833-334-9924.